Therapeutic innovation & regulatory science
Patient-Perceived Overall Side Effect Bother at and After Cancer Treatment Discontinuation: An Analysis Using Commercial Cancer Trial Data.
Jessica Roydhouse, Monique Breslin, Anne Zola, Ethan Basch, Melanie Calvert, David Cella, Mary Lou Smith, Gita Thanarajasingam, John Devin Peipert
Published: 202610.1007/s43441-025-00906-8
Abstract
INTRODUCTION: There is widespread interest among patients, clinicians, regulators and other constituents in post-treatment patient-reported cancer data. Side effect bother is a patient-reported outcome (PRO) that can capture an important aspect of to…
Preview only. Read the full abstract at the source